[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"dupuytrens-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:dupuytrens-disease":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,41,65,96,113,136,162],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100540834","phase-2-nodular-shrinking-in-dupuytren-disease-100540834",false,"NCT06321991","Nodular Shrinking in Dupuytren Disease","Nodular Shrinking in Stage 0 Dupuytren Disease: an Evidence-based Approach for Early Stage Treatment to Prevent Progression to Advanced Finger Contractures","Echo","Inclusion Criteria:\n\n* The participant or his\u002Fher legally authorized representative voluntary signed the informed consent prior to the first assessment.\n* Participants are ≥ 18 years and diagnosed with primary Dupuytren disease.\n* Included patients have a stage 0 DD (nodule of at least 5 mm in the involved hand without contracture).\n* The participant has well distinguished noduli that are clearly visible on US (ultrasound)\n\nExclusion Criteria:\n\n* Patients \\\u003C 18 years.\n* Patient included in an interventional trial with an investigational medicinal product.\n* Patients with cognitive impairments, severe rheumatic disease and neurological disorders leading to flexion deformities of the fingers.\n* Patients with prior Dupuytren surgery in the involved hand.\n* Patients with a higher Tubiana grading than nodular stage 0.\n* Open wound in the palm of the treated hand.","ALL","18 Years",{"count":20,"type":21},80,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","Dupuytren disease (DD) is a common hand disorder with disabling finger contractures that may require surgery to restore function. In the early stages of the disease, the nodules (Tubiana stage 0) are usually painless, but a reason for concern to many patients. Not rarely, lifestyle measures and even risky treatment options as radiotherapy are advised, yet no therapy to prevent disease evolution has a solid proven effect. Furthermore, reliable non-invasive measurement of early stage DD is not validated.\n\nEvidence was found that pharmacotherapy may influence DD evolution, but valuable clinical trials are limited. Case series and non-published explorative follow-up suggested local treatment with antioxidant vitamin E to possibly interfere with an evolution of DD nodules to contracting strands. This study aims to provide evidence on efficiency of this non-invasive treatment option.\n\nSecure measurement of nodule evolution is a clinical challenge. To measure this evolution, ultrasound and MRI scanning are currently being performed. Stage 0 (nodules) is more challenging to quantify. A strict individual follow-up by the treating clinician is needed to standardize measurement of selected (treated) nodules. Therefore, simple ultrasound by the treating clinician may provide an good tool to collect data. This study aims to introduce and validate this non-invasive scan method and provide a prospective double blind investigation of a measurable effect of non-invasive preventive treatment for stage 0 DD to improve clinical outcome.",[27],"Dupuytren's Disease","RECRUITING","2026-05-05",{"date":31,"type":32},"2026-05-11","ACTUAL",{"date":34,"type":32},"2024-02-15",{"date":36,"type":21},"2027-03-01",{"name":38,"class":39},"Universitaire Ziekenhuizen KU Leuven","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":51,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":64},"100444464","efficacy-of-aponeurectomy-on-the-2-year-recurrence-rate-of-dupuytrens-disease-100444464","NCT05067764","Efficacy of Aponeurectomy on the 2-year Recurrence Rate of Dupuytren's Disease","Multicenter, Randomized, Open-label Study Evaluating the Efficacy of Aponeurectomy Associated With Adipose Tissue Grafting Compared to Aponeurectomy Alone, on the 2-year Recurrence Rate of Dupuytren's Disease (REMEDY).","REMEDY","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Carrier of Tubiana stage II-IV Dupuytren's disease on at least one or more rays, not previously operated\n* Indication of a surgery by aponeurectomy\n* Skin pinch of the posterior aspect of the arm of more than 1cm\n* Affiliation to a social security system\n* Patient informed of the study and having given informed consent\n\nExclusion Criteria:\n\n* Previous surgery of any kind for Dupuytren's disease\n* Involvement on the thumb only\n* Need for a total skin graft or a pedicle flap on all the rays to be treated\n* Active autoimmune disease\n* Previous treatment with collagenase\n* Pregnant and breastfeeding women\n* Patient under legal protection\n* Contraindications to MRI (criteria applicable only for patients from the coordinating center, not applicable for other centers)",{"count":50,"type":21},172,[52],"NA","Dupuytren's disease is a frequent hereditary disease in Northern Europe. It is a degenerative disease affecting the palmar aponeurosis of the hand. It develops a progressive contractile fibrosis which cuts the hypodermic fatty tissue, adheres to the skin and the phalanges, gradually bending the affected rays, resulting in significant functional impotence.\n\nVarious medical and surgical treatments are available.",[27],"2026-04-20",{"date":57,"type":32},"2026-04-23",{"date":59,"type":32},"2022-09-29",{"date":61,"type":21},"2030-03-29",{"name":63,"class":39},"Elsan",2,{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":4,"eligibilityCriteria":71,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":72,"targetDuration":4,"studyType":74,"phases":4,"briefSummary":75,"conditions":76,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":40},"100371894","post-contracture-release-radiation-for-dupuytrens-disease-100371894","NCT04122313","Post-contracture Release Radiation for Dupuytren's Disease","Efficacy of Post-contracture Release Radiation for the Treatment of Dupuytren's Disease","Inclusion Criteria:\n\n* Diagnoses of Dupuytren's disease\n* English-speaking\n\nExclusion Criteria:\n\n\\- Patients with Dupuytren's disease who are not currently seeking treatment",{"count":73,"type":21},50,"OBSERVATIONAL","To determine if the clinical impression of clinicians, ie that patients are improving with the current treatment pathway for Dupuytren's (contracture release followed by radiation), can be substantiated with scientific evidence.",[27,77,78,79,80,81,82,83,84,85,86],"Dupuytren Contracture","Dupuytren Disease of Palm and Finger","Dupuytren Disease of Finger","Dupuytrens Contracture of Both Hands","Dupuytren's Disease of Palm of Right Hand","Dupuytren's Disease of Palm of Left Hand","Dupuytren Contracture of Right Palm","Dupuytren Contracture of Left Palm","Dupuytren's Contracture Left","Dupuytren's Contracture Right","2026-03-16",{"date":89,"type":32},"2026-03-19",{"date":91,"type":32},"2019-05-31",{"date":93,"type":21},"2029-03-01",{"name":95,"class":39},"University of Minnesota",{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":102,"eligibilityCriteria":103,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":104,"targetDuration":4,"studyType":74,"phases":4,"briefSummary":105,"conditions":106,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":112,"locationsCount":40},"100527066","micronerves-in-dupuytren-and-the-impact-of-its-dissection-on-recurrence-100527066","NCT06142929","Micronerves in Dupuytren and the Impact of Its Dissection on Recurrence","Observational Study on Small Nerve Bundles in Dupuytren Disease and the Impact of Its Dissection on Recurrence.","Micronerves","Inclusion criteria:\n\nParticipants eligible for inclusion in this study must meet all of the following criteria:\n\n1. The participant or his\u002Fher legally authorized representative voluntary signed the informed consent prior to the first assessment\n2. Participants are ≥ 18 years and diagnosed with primary\u002Frecurrent Dupuytren disease\n3. Included patients are eligible for microfasciectomy\n\nExclusion criteria:\n\nParticipants eligible for this study must not meet any of the following criteria:\n\n1. Patients \\\u003C 18 years\n2. Patient included in an interventional trial with an investigational medicinal product\n3. Patients with cognitive impairments, severe rheumatic disease and neurological disorders leading to flexion deformities of the fingers",{"count":20,"type":21},"Dupuytren disease (DD) is a highly prevalent disabling hand disease. Spontaneous fibrosis nodules and strands in the palms of the hand cause finger contractures in disturbing positions and movement restrictions. Finger movement can be restored by surgery (removing the fibrosis tissue), but recurrence is a major problem and this is difficult to treat.\n\nThrough microfasciectomy, the presence of small nerve bundles (micronerves) were observed. These nerves are possibly related to the hand fascia, which is the origin of Dupuytren disease. These micornerves and their dissection could play a role in the recurrence of DD. This study will investigate the role of these micronerves in DD, the impact of its dissection on formation of neuromas and on recurrence.\n\nAlso, the presence of nerve growth factor (NGF) will be evaluated. The purpose is to provide information on potential neuro-induced fibrosis.",[27],"2026-03-12",{"date":87,"type":32},{"date":110,"type":32},"2024-01-01",{"date":36,"type":21},{"name":38,"class":39},{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":119,"eligibilityCriteria":120,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":121,"targetDuration":4,"studyType":22,"phases":123,"briefSummary":124,"conditions":125,"keywords":4,"overallStatus":126,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":40},"100620087","prognostic-profile-of-dupuytrens-disease-a-cohort-study-product-100620087","NCT07353060","Prognostic Profile of Dupuytren's Disease: a Cohort Study (PRODUCT)","Prognostic Profile of Dupuytren's Disease: a Cohort Study","PRODUCT","Inclusion Criteria:\n\n* Patient, male or female, over 18 years of age\n* Patient with Dupuytren's disease confirmed by clinical examination: nodule or cord arising from the superficial palmar aponeurosis, visible or palpable\n* Aponeurotic cord causing an MCP or PIP joint flexion contracture of at least 20°\n* Indication for percutaneous needle ablation (flexion contracture of at least 20°, functionally impaired according to the patient)\n* Acceptance of percutaneous needle ablation by the patient\n* Patient affiliated with or covered by a social security scheme\n* Patient having been informed and having signed a free and informed written consent\n* Negative urine pregnancy test for women of childbearing age\n\nExclusion Criteria:\n\n* Minor patient,\n* Patient with another condition, infection, or wound of the hand,\n* Patient participating in another clinical trial,\n* Protected patient: adult under guardianship, curatorship, or other legal protection, deprived of liberty by judicial or administrative decision,\n* Person unable to express their consent,\n* Pregnant, breastfeeding, or parturient woman",{"count":122,"type":21},305,[52],"Dupuytren's disease is characterized by retractile fibrosis of the superficial palmar aponeurosis, which can lead to irreversible flexion contractures of the fingers and lasting functional impairment. Widespread throughout the world, it has a particularly high prevalence in northern European countries. This has been estimated at between 3.5% and 11% in England and Denmark. This prevalence is expected to increase over time due to the aging population. Risk factors for the disease include age, male sex, heredity, diabetes, smoking, and alcohol consumption. The resulting disability is not spontaneously reversible. It affects various aspects of daily life, most notably personal care, nutrition, and social interaction.\n\nTreatment for Dupuytren's disease, whether medical or surgical, remains symptomatic to date and does not preclude the possibility of recurrence. In France, it is based on percutaneous needle aponeurotomy and surgical aponeurectomy. Its objectives are to reduce the flexion contracture of the fingers and the functional disability caused by the disease. Enzymatic aponeurosis with collagenase is also possible, but it is less well tolerated than percutaneous needle aponeurotomy. It is more expensive and not covered by health insurance.\n\nThe widespread adoption of a medical-surgical strategy that positions percutaneous needle aponeurotomy as the first-line treatment could improve the acceptability of Dupuytren's disease treatment and significantly reduce its cost to healthcare systems. However, the impact of this strategy depends on the extent to which second-line surgery is required. This use has been little studied. The proportion of patients requiring surgical treatment after percutaneous needle aponeurotomy is estimated to be 10 to 18%. These data are based on small sample sizes observed over varying follow-up periods. They need to be verified in large populations using a prospective study. Moreover, the factors associated with the need for surgery after percutaneous needle ablation for Dupuytren's disease are currently poorly understood. Understanding these factors would be beneficial for optimizing medical and surgical management. It could allow for better tailoring of treatment options to the patient's individual profile.",[27],"NOT_YET_RECRUITING","2026-01-13",{"date":129,"type":32},"2026-01-20",{"date":131,"type":21},"2026-02-04",{"date":133,"type":21},"2031-02-04",{"name":135,"class":39},"Ramsay Générale de Santé",{"id":137,"slug":138,"hasResults":11,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":4,"eligibilityCriteria":142,"healthyVolunteers":143,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":144,"targetDuration":4,"studyType":22,"phases":146,"briefSummary":147,"conditions":148,"keywords":149,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":152,"lastUpdatePostDateStruct":153,"startDateStruct":155,"completionDateStruct":157,"leadSponsor":159,"locationsCount":161},"100462379","effectiveness-of-night-splinting-after-percutaneous-needle-fasciotomy-in-dupuytrens-contracture-100462379","NCT05300893","Effectiveness of Night Splinting After Percutaneous Needle Fasciotomy in Dupuytren's Contracture","Effectiveness of Night Splinting After Percutaneous Needle Fasciotomy in Dupuytren's Contracture - a Randomised Controlled Multicenter Trial","Inclusion Criteria:\n\n* 18 years of age and older,\n* Palpable Dupuytren strand with passive extension deficit according to stadium 1 and 2 of the classification of Tubiana in one or two fingers excluding the thumb, defined as at least 30 degrees in the MCP joint and\u002For at least 20 degrees in the PIP joint and a maximum of 75 degrees in the MCP or PIP joint\n\nExclusion Criteria:\n\n* Multiple, invasive or wide strands in the palm,\n* Skin irritation,\n* Strand localization in the digit only,\n* Digital nerve injury,\n* Any former treatment for Dupuytren's contracture in the same digit,\n* Thumb contracture,\n* Stadium 3 and 4 according to the classification of Tubiana",true,{"count":145,"type":21},154,[52],"Dupuytren's contracture (DC) is associated with progressive finger flexion and extension deficit caused by fibrosis in the palm and digits. Treatment options include minimally invasive procedures such as percutaneous needle fasciotomy (PNF) and collagenase clostridium histolyticum injections as well as open fasciectomy. PNF has recently become more popular in Sweden because it is an office-based procedure which is relatively easy to perform without the usual risks and costs of open surgery.\n\nAfter treatment with PNF patients usually continue with supervised rehabilitation, which includes physical therapy and night splinting. Whether night splinting is beneficial in terms of reducing recurrence of DC is currently debated.\n\nThis study aims to investigate whether night splinting after performed PNF helps to reduce recurrence rate or not. Patients who meet the inclusion criteria will be randomized into two groups: The first group will be treated as usual with physical therapy and night splinting after PNF. The second group will be treated with physical therapy without night splinting after PNF. Follow up includes physical examination regarding active range of motion, sensation and grip strength at procedure day and 2 weeks, 3, 12 and 36 months later as well as questionnaires regarding hand function, pain and quality of life at procedure day and 3, 12 and 36 months later. Patients who are randomized into the second group (no night splinting) will also be examined 3 weeks after PNF for observation in case of an early impairment regarding extension deficit.",[77,27],[150,151],"Percutaneous needle fasciotomy","Splint","2024-05-30",{"date":154,"type":32},"2024-05-31",{"date":156,"type":32},"2022-09-14",{"date":158,"type":21},"2027-01",{"name":160,"class":39},"Uppsala University",3,{"id":163,"slug":164,"hasResults":11,"nctId":165,"briefTitle":166,"officialTitle":167,"acronym":4,"eligibilityCriteria":168,"healthyVolunteers":11,"sex":17,"minAge":169,"maxAge":170,"enrollmentInfo":171,"targetDuration":4,"studyType":22,"phases":173,"briefSummary":175,"conditions":176,"keywords":187,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":190,"lastUpdatePostDateStruct":191,"startDateStruct":193,"completionDateStruct":195,"leadSponsor":197,"locationsCount":40},"100473080","phase-4-percutaneous-needle-fasciotomy---corticosteroid-injection-for-dupuytrens-contracture-100473080","NCT05440240","Percutaneous Needle Fasciotomy +\u002F- Corticosteroid Injection for Dupuytren's Contracture","Percutaneous Needle Fasciotomy (PNF) +\u002F- Corticosteroid Injection for Dupuytren's Contracture (DC) Affecting Metacarpophalangeal Joints (MCP) . A Randomized Controlled Trial","Sufficient correction of metacarpophalangeal (MCP) joint during the PNF treatment, defined as \\\u003C20° passive extension deficit (PED), is a prerequisite for inclusion.\n\nInclusion Criteria:\n\n* Dupuytren contracture (DC) of ≥ 20° PED in MCP joint measured with a goniometer\n* DC of either II-V finger\n* Well-defined\u002Fpalpable cord\n\nExclusion Criteria:\n\n* Legally incapacitated\n* Previous study inclusion with another finger ray\n* Isolated proximal interphalangeal (PIP) or distal interphalangeal (DIP) joint contracture, defined as MCP joint contracture \\\u003C 20° PED regardless of the deficit in the PIP or DIP joint\n* Previous hand surgery of the affected finger for any reason\n* Known allergy to the study medication\n* Anticoagulant therapy (Acetylsalicylic acid is NOT an exclusion criterion)\n* Pregnant or lactation\n* Insulin dependent diabetes mellitus\n* Ongoing systemic infection or local infection at the site of the procedure\n* Rheumatoid arthritis\n* Amyloidosis or mucopolysaccharidosis\n* Unable to communicate, cooperate or participate in follow-up","45 Years","99 Years",{"count":172,"type":21},400,[174],"PHASE4","Comparing percutaneous needle fasciotomy +\u002F- corticosteroid injection for Dupuytren's contracture affecting metacarpophalangeal joints. A clinician-initiated, multicenter, randomized controlled trial.",[77,27,177,178,179,180,181,182,183,184,185,186],"Contracture","Joint Diseases","Musculoskeletal Diseases","Fibroma","Neoplasm, Fibrous Tissue","Neoplasms, Connective Tissue","Neoplasms, Connective and Soft Tissue","Neoplasms by Histologic Type","Neoplasms","Connective Tissue Diseases",[150,188,189],"Corticosteroid","Randomized controlled trial","2023-05-15",{"date":192,"type":32},"2023-05-17",{"date":194,"type":32},"2023-01-10",{"date":196,"type":21},"2030-03",{"name":198,"class":39},"Regionshospitalet Silkeborg"]